Duo of Nordic IPOs Surge Above Offer Prices in Early Trading
Two initial public offerings in the Nordics traded substantially above their offer prices on Friday, cementing a trend of strong debuts in the region.
Shares in specialist mortgage lender Enity Holding AB jumped as much as 32% in early trading after raising about 1.45 billion krona ($150 million) in Stockholm. Ratos AB 's Nordic construction unit Sentia AS also traded strongly with shares opening 14% higher than its IPO price in Oslo.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
43 minutes ago
- Forbes
The Chime IPO Will Kickstart A Fintech Investment Comeback
Chris Britt, co-founder and chief executive officer of Chime Financial Inc., during the company's ... More initial public offering at the Nasdaq MarketSite in New York, US, on Thursday, June 12, 2025. Chime launched its IPO with a splash. Shares jumped as much as 59% above the $27 offering price—opening at $43 and closing near $37—marking a bold public debut for the US's largest neobank. With a valuation hovering between $11.6 billion and $15 billion—well below its 2021 private peak of $25 billion—the surge raises the question: Will this trigger renewed investment in neobanks and fintech? Chime's IPO follows strong debuts from fintechs like Circle and eToro. PitchBook's Rudy Yang framed Chime as 'a strategic breakthrough—marking a return of fintech liquidity' after the sector saw VC exit values plummet from $222 billion in 2021 to under $30 billion in the past few years. Chime could be a bellwether for a neobank--and broader fintech--recovery if it: There is another side of the coin: Is Chime's IPO really a pivotal moment for the fintech industry and a validation of the digital-banking model and a template for future bank challengers? No. Chime's debut feels more like a secure base camp than a flag planted atop Everest. It suggests that public markets are open to credible fintech challengers—provided they bring scale, strong unit economics, and realistic valuations. The critical questions for neobanks: 1) Can they diversify revenue beyond interchange (loans, wealth, insurance)? 2) Will macro conditions hold stable enough to sustain IPO markets? 3) Will consumer-trust and customer growth trajectories support future public offerings? The answers are no. There are market factors impacting neobanks that have closed the door to new neobanks coming into the market: 1) Megafintechs have better economics and business models. Among consumers who consider a digital bank or neobank their primary checking account or payments provider, half of them say their primary provider is PayPal or Square Cash App. Neobanks don't just compete with incumbent banks—they compete with the megafintechs, whose platform business models give them scale and revenue diversity. 2) Interchange isn't a reliable revenue source. Relying on interchange runs against consumer behavior trends regarding: 3) The niche affinity play is tough for startups. This strategy requires neobanks to identify a segment's unique financial needs and Be the dominant affinity. Neobanks' claims of how big their affinity groups are misleading because most of us belong to multiple affinity groups. Fintech has entered a new phase—one defined by realism, consumer impact, and long-term value creation. The new phase, however, isn't about bank disruption and displacement--it's about banking industry infrastructure upgrade and replacement. The Chime IPO will help create more VC interest in fintech investment--but that investment won't go to new neobanks. Instead, it will go to startups that bring two things to the financial services industry: 1) AI-driven process reinvention from machine learning, Generative AI, and Agentic AI tools and technologies, and 2) Stablecoin and other cryptocurrency-related payments innovation. The latter may do more to disrupt banks than Chime and other neobanks have done.
Yahoo
an hour ago
- Yahoo
MGP Ingredients (NASDAQ:MGPI) investors are sitting on a loss of 68% if they invested three years ago
The truth is that if you invest for long enough, you're going to end up with some losing stocks. Long term MGP Ingredients, Inc. (NASDAQ:MGPI) shareholders know that all too well, since the share price is down considerably over three years. Unfortunately, they have held through a 69% decline in the share price in that time. And more recent buyers are having a tough time too, with a drop of 61% in the last year. More recently, the share price has dropped a further 10% in a month. So let's have a look and see if the longer term performance of the company has been in line with the underlying business' progress. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). MGP Ingredients saw its EPS decline at a compound rate of 54% per year, over the last three years. This fall in the EPS is worse than the 32% compound annual share price fall. So the market may not be too worried about the EPS figure, at the moment -- or it may have previously priced some of the drop in. This positive sentiment is also reflected in the generous P/E ratio of 57.06. The image below shows how EPS has tracked over time (if you click on the image you can see greater detail). It's good to see that there was some significant insider buying in the last three months. That's a positive. That said, we think earnings and revenue growth trends are even more important factors to consider. It might be well worthwhile taking a look at our free report on MGP Ingredients' earnings, revenue and cash flow. MGP Ingredients shareholders are down 60% for the year (even including dividends), but the market itself is up 12%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 3% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 4 warning signs for MGP Ingredients you should be aware of. MGP Ingredients is not the only stock insiders are buying. So take a peek at this free list of small cap companies at attractive valuations which insiders have been buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Why Eagle Materials Inc. (NYSE:EXP) Could Be Worth Watching
While Eagle Materials Inc. (NYSE:EXP) might not have the largest market cap around , it received a lot of attention from a substantial price movement on the NYSE over the last few months, increasing to US$242 at one point, and dropping to the lows of US$196. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Eagle Materials' current trading price of US$196 reflective of the actual value of the mid-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let's take a look at Eagle Materials's outlook and value based on the most recent financial data to see if there are any catalysts for a price change. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Good news, investors! Eagle Materials is still a bargain right now according to our price multiple model, which compares the company's price-to-earnings ratio to the industry average. We've used the price-to-earnings ratio in this instance because there's not enough visibility to forecast its cash flows. The stock's ratio of 13.83x is currently well-below the industry average of 19.13x, meaning that it is trading at a cheaper price relative to its peers. What's more interesting is that, Eagle Materials's share price is quite volatile, which gives us more chances to buy since the share price could sink lower (or rise higher) in the future. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market. View our latest analysis for Eagle Materials Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it's the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. With profit expected to grow by a double-digit 20% over the next couple of years, the outlook is positive for Eagle Materials. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation. Are you a shareholder? Since EXP is currently below the industry PE ratio, it may be a great time to increase your holdings in the stock. With a positive outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current price multiple. Are you a potential investor? If you've been keeping an eye on EXP for a while, now might be the time to enter the stock. Its prosperous future profit outlook isn't fully reflected in the current share price yet, which means it's not too late to buy EXP. But before you make any investment decisions, consider other factors such as the track record of its management team, in order to make a well-informed assessment. With this in mind, we wouldn't consider investing in a stock unless we had a thorough understanding of the risks. Every company has risks, and we've spotted 1 warning sign for Eagle Materials you should know about. If you are no longer interested in Eagle Materials, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
